The formation of thrombi in vivo includes the activation of both platelets and the coagulation cascade. Conventional thrombolytic therapy is primarily directed toward the dissolution of fibrin. To evaluate the possibility that platelet activity impairs the lysis of thrombi, we studied the effects of aspirin and platelet-deaggregating prostaglandin El on thrombolysis with urokinase. Combined platelet and fibrin thrombi were produced in vitro by adding CaCI2 and collagen (1 ,ug/ml) to citrated platelet-rich plasma (250,000 platelets per ,ul). Urokinase (500-10,000 units/ml) caused a dose-dependent weight loss of the thrombi that was maximal at 2,000 units/ml. The addition of aspirin (10-200 ,ug/ml) to platelet-rich plasma before thrombus formation markedly enhanced thrombolysis with urokinase. This effect was most pronounced at 20 ,ug/ml aspirin. However, when aspirin was added after completion of thrombus formation, no significant effect on thrombolysis was noted. Prostaglandin E, (1-100 ,mol/l) improved the lysis with urokinase of the combined platelet and fibrin thrombi. This effect was maximal at 20 ,umol/l prostaglandin E1. When pure fibrin thrombi were produced in platelet-free plasma, prostaglandin E1 was without effect on lysis. Thus, in vitro lysis with urokinase of combined platelet and fibrin thrombi was enhanced by the addition of platelet-deaggregating prostaglandin E1 and by pretreatment with aspirin. (Circulation 1989;79:1309-1314 T hrombus formation in vivo is the result of a complex interaction between blood components and the vessel wall.' It includes the activation of both platelets and the coagulation system. Conventional thrombolytic therapy is primarily directed toward the dissolution of fibrin, the final product of the coagulation cascade. In 
T hrombus formation in vivo is the result of a complex interaction between blood components and the vessel wall.' It includes the activation of both platelets and the coagulation system. Conventional thrombolytic therapy is primarily directed toward the dissolution of fibrin, the final product of the coagulation cascade. In an in vitro model of combined platelet and fibrin thrombus formation, we studied the effects of aspirin and prostaglandin El on thrombolysis with urokinase. Aspirin inhibits platelets by irreversible acetylation of platelet cyclooxygenase.2,3 Prostaglandin El is a platelet inhibitory compound4-9 and has the additional capacity of deaggregating aggregated platelets.4,8 10 These actions of prostaglandin El are generally thought to be mediated by an elevation of platelet cyclic AMP levels.5-7 9 
Methods
The experiments were conducted on blood from 20 apparently healthy and nonsmoking volunteers, 12 men and eight women, with a mean age of 25.2 years (range, 22-29 years). All claimed not to have taken any drugs during 14 days before blood collection. For each experimental condition, 10-13 series of experiments were performed on blood from 10-13 donors. The blood was collected from a large antecubital vein through a needle of 1.1-mm internal diameter into a plastic syringe. Nine parts of blood were mixed in the syringe with one part of 3.13% Na-citrate.
The blood was centrifuged at 300g for 10 minutes. After removal of the platelet-rich plasma, the remaining blood was centrifuged at 2,500g for 10 minutes. Platelet-free plasma was produced by centrifugation of the supernatant plasma at 8,000g for another 5 minutes. Platelets in platelet-rich plasma were counted under a light microscope, and platelet-rich and platelet-free plasma were mixed to achieve a final count of 250,000 plateletsl,l.
Aliquots of 500 gul of this standardized plateletrich plasma were incubated for 5 minutes at 370 C in Histologic examination revealed that the thrombi produced in platelet-free plasma were pure fibrin thrombi. After thrombus formation, the levels of fibrinogen in the plasma surrounding the thrombus had decreased by 98-99%.
Statistics
Statistical comparisons were performed with Student's t tests for paired or for unpaired data. A p value of 0.05 or less was considered to be significant. All values indicated are mean+SEM.
Results
The thrombi (n =308) formed in platelet-rich plasma (250,000 platelets/,li) had a mean weight of 20.6±0.2 mg. In the control experiments (n=35 in the three series displayed in Figures 1, 3 , and 4) in which no active compounds were added to the thrombi, thrombus weight during 30 minutes decreased to 70.4+1.3% of baseline. This decrease in thrombus weight was associated with almost no change in the light transmission of the plasma surrounding the thrombi (-0.6+0.2%).
The in vitro application of urokinase (500-10,000 units/ml) caused dose-dependent thrombolysis ( Figure  1 ). The weight loss of the thrombi reached a maximum at 2,000 units/ml urokinase. When aspirin (10-200 .g/ml) was added to plateletrich plasma before thrombus formation, the mean thrombus weights at baseline for the different concentrations of aspirin ranged between 19.6±0.6 and 20.6±0.8 mg and were, thus, identical to the value of 20.4±1.0 mg in the control experiments without aspirin in the same persons at the same blood collections. However, pretreatment of the plasma with aspirin markedly enhanced thrombolysis with urokinase (2,000 units/ml, Figure 2 ). The effect of aspirin pretreatment on thrombus weight was significant at concentrations of 10-100 gg/ml, and plasma light transmission decreased significantly more after aspirin at 10-50 yg/ml than in the respective control experiments without aspirin. The effect of pretreating the plasma with aspirin both on thrombus weight and plasma light transmission was maximal at a concentration of aspirin of 20 g.tg/ml. After 20 , ug When aspirin was added to the plasma after completion of thrombus formation, thrombolysis with urokinase was not significantly affected ( Figure 3 ). This was true for all concentrations of aspirin tested (10-200 ,ug/ml) and for its effect on both thrombus weight and light transmission of the plasma (Figure 3 31 .5±1.5 mg (n=30) and, thus, significantly higher than that of the thrombi produced in platelet-rich plasma (p<0.0001). In the control experiments (n = 10) with no active compound added to the thrombi, thrombus weight measured after 30 minutes had declined to 52.5 ±2.1% of baseline and, thus, in absolute values had become similar to the weight after 30 minutes of the control thrombi produced in platelet-rich plasma. For the thrombi produced in platelet-free plasma, prostaglandin E1 (20 ,umol/l) did not enhance lysis with urokinase (2,000 units/ml, Figure 5 ). Discussion In this study we dose dependent and maximal above certain concentrations of the two agents.4-7,9,13-15 To our knowledge, there are no data to explain the apparent decrease in the supportive effect on thrombolysis seen with concentrations of both drugs that exceed the most effective concentrations in our experiments.
In our study, the most effective concentrations in vitro were 20 ,ug/ml for aspirin and 20 When infused intra-arterially, the local concentration of prostaglandin El mainly depends on blood flow and on uptake by endothelial and blood cells. As a result, the "best dose" to be applied into an occluded artery also cannot be derived from our in vitro studies but must be evaluated clinically.
In our experiments when aspirin was added to the plasma after completion of thrombus formation, no significant effect on lysis was observed. Thus, the positive effect of aspirin on the mortality of patients with myocardial infarction and undergoing thrombolytic therapy25 may be explained by an inhibition of reocclusion of the vessel opened by thrombolySiS26 rather than by an increase in the primary efficacy of lysis. Although no morphologic difference was noted between thrombi formed in vitro in the presence or absence of aspirin, a less stable architecture of the platelet part of the thrombi formed under the influence of aspirin may have been the cause of the increased extent of thrombus lysis with urokinase. When prostaglandin El was used in lysing thrombi produced in platelet-free plasma, no effect in addition to that of urokinase was observed. Thus, the positive effect of prostaglandin El was linked to the presence of platelets in the thrombus.
The different thrombolytic regimens evaluated in our study differently affected the light transmission of the plasma surrounding the thrombi undergoing lysis. A decrease in the light transmission of plasma may either be produced by an increase in the number of particles present in the plasma or by a decrease in the size of the particles with constant total particle mass. The decrease in thrombus weight seen in the experiments where no active compounds were added to the thrombi was associated with almost no change in the light transmission of the surrounding plasma. This was true for thrombi formed in both platelet-rich and platelet-free plasma. Because it did not coincide with a change in light transmission of the plasma, the decrease in thrombus weight in the control experiments during 30 minutes of storage of plasma must, thus, reflect a loss of plasma from the thrombus.
When thrombi were lysed with increasing concentrations of urokinase, plasma light transmission continuously decreased, while the reduction in thrombus weight was greatest at a concentration of 2,000 units/ml urokinase. Thus, above that concentration, urokinase, despite a decrease in its thrombolytic potential, must have produced a decrease in the size of the particles dissolved from the thrombi. In addition, by comparing the effect on thrombolysis of aspirin pretreatment to that of adding prostaglandin El to urokinase, aspirin was found to be more effective than prostaglandin El in reducing thrombus weight. In contrast, the effect of prostaglandin El on plasma light transmission was considerably larger than that of aspirin. Thus, prostaglandin EB must have led to a larger decrease in the size of the particles lysed from the thrombus.
What could be the clinical implications of these results? In patients with acute myocardial infarction undergoing thrombolytic therapy, aspirin pretreatment may significantly increase the rate and extent of coronary artery reopening. In addition, thrombi generated under the influence of aspirin may more frequently be dissolved by the body's own thrombolytic mechanisms. The effect of aspirin described here may thereby contribute to the favorable effect of aspirin on the incidence of acute myocardial infarction observed in secondary27-36 and primary prevention trials. 37 The observed effects of prostaglandin El in enhancing thrombolysis with urokinase should stimulate present attempts to evaluate this substance under clinical conditions.38,39 However, with both adjunctive antiplatelet approaches, an increased bleeding tendency under in vivo conditions may limit the benefit for patients.
In conclusion, focussing on the platelet part of the thrombus by either inhibiting platelets before thrombus formation or deaggregating platelets after completion of thrombus formation may be useful to further enhance the efficacy of thrombolytic therapy in vivo. In the clinical setting, however, an increased bleeding tendency could be a limitation.
